Short Report

Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings

Volume: 5 Number: 3 January 13, 2026
Molecular Oncologic Imaging Cover
Molecular Oncologic Imaging
PDF Download

Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings

Abstract

Dedifferentiated liposarcoma (DDLPS) is a rare and aggressive soft tissue sarcoma most commonly arising in the retroperitoneum, but it can also occur in uncommon sites such as the paratesticular region. We present two cases of DDLPS with distinct clinical presentations and highlight the diagnostic and prognostic utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). The first case describes a retroperitoneal DDLPS in a female patient with intense FDG uptake. In contrast, the second case presents a paratesticular DDLPS in a male patient with recurrence and metastatic progression on PET/CT imaging despite chemoradiotherapy. These cases emphasize the role of FDG PET/CT in staging and biopsy guidance and in monitoring treatment response and prognosis.

Keywords

References

  1. 1. Haddox, C. L., Hornick, J. L., Roland, C. L., Baldini, E. H., Keedy, V. L., & Riedel, R. F. (2024). Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement. Cancer treatment reviews, 131, 102846. https://doi.org/10.1016/j.ctrv.2024.102846
  2. 2. Lee, A. T. J., Thway, K., Huang, P. H., & Jones, R. L. (2018). Clinical and Molecular Spectrum of Liposarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36(2), 151–159. https://doi.org/10.1200/JCO.2017.74.9598
  3. 3. Dehner, C. A., Hagemann, I. S., & Chrisinger, J. S. A. (2021). Retroperitoneal Dedifferentiated Liposarcoma. American journal of clinical pathology, 156(5), 920–925. https://doi.org/10.1093/ajcp/aqab051
  4. 4. Kamitani, R., Matsumoto, K., Takeda, T., Mizuno, R., & Oya, M. (2020). Optimal treatment strategy for paratesticular liposarcoma: retrospective analysis of 265 reported cases. International journal of clinical oncology, 25(12), 2099–2106. https://doi.org/10.1007/s10147-020-01753-3
  5. 5. Kamitani, R., Matsumoto, K., Takeda, T., Mizuno, R., & Oya, M. (2020). Optimal treatment strategy for paratesticular liposarcoma: retrospective analysis of 265 reported cases. International journal of clinical oncology, 25(12), 2099–2106. https://doi.org/10.1007/s10147-020-01753-3
  6. 6. Rhu, J., Hyun, S. H., Lee, K. H., Jo, S. J., Lee, K. W., Park, J. B., & Kim, S. J. (2019). Maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography/computed tomography improves outcome prediction in retroperitoneal liposarcoma. Scientific reports, 9(1), 6605. https://doi.org/10.1038/s41598-019-43215-5
  7. 7. Liu, D. N., Li, Z. W., Wang, H. Y., Zhao, M., Zhao, W., & Hao, C. Y. (2018). Use of 18F-FDG-PET/CT for Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas. Contrast media & molecular imaging, 2018, 2601281. https://doi.org/10.1155/2018/2601281
  8. 8. Baffour, F. I., Wenger, D. E., & Broski, S. M. (2020). 18F-FDG PET/CT imaging features of lipomatous tumors. American journal of nuclear medicine and molecular imaging, 10(1), 74–82.

Details

Primary Language

English

Subjects

Nuclear Medicine

Journal Section

Short Report

Authors

Publication Date

January 13, 2026

Submission Date

October 3, 2025

Acceptance Date

October 16, 2025

Published in Issue

Year 2025 Volume: 5 Number: 3

DOI

https://doi.org/10.71286/moi.1794676

IZ

https://izlik.org/JA42HH96MJ

Cite

RIS / Bibtex
APA
Yılmaz Bildik, B., Beyhan, E., Tosunoğlu, Z., Öztürk, A. E., Alçın, G., Akgün, E., & Arslan, E. (2026). Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings. Molecular Oncologic Imaging, 5(3), 4-9. https://doi.org/10.71286/moi.1794676
AMA
1.Yılmaz Bildik B, Beyhan E, Tosunoğlu Z, et al. Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings. Molecular Oncologic Imaging. 2026;5(3):4-9. doi:10.71286/moi.1794676
Chicago
Yılmaz Bildik, Bengisu, Ediz Beyhan, Zehranur Tosunoğlu, et al. 2026. “Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations With FDG PET CT Findings”. Molecular Oncologic Imaging 5 (3): 4-9. https://doi.org/10.71286/moi.1794676.
EndNote
Yılmaz Bildik B, Beyhan E, Tosunoğlu Z, Öztürk AE, Alçın G, Akgün E, Arslan E (January 1, 2026) Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings. Molecular Oncologic Imaging 5 3 4–9.
IEEE
[1]B. Yılmaz Bildik et al., “Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings”, Molecular Oncologic Imaging, vol. 5, no. 3, pp. 4–9, Jan. 2026, doi: 10.71286/moi.1794676.
ISNAD
Yılmaz Bildik, Bengisu - Beyhan, Ediz - Tosunoğlu, Zehranur - Öztürk, Ahmet Ertuğrul - Alçın, Göksel - Akgün, Elife - Arslan, Esra. “Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations With FDG PET CT Findings”. Molecular Oncologic Imaging 5/3 (January 1, 2026): 4-9. https://doi.org/10.71286/moi.1794676.
JAMA
1.Yılmaz Bildik B, Beyhan E, Tosunoğlu Z, Öztürk AE, Alçın G, Akgün E, Arslan E. Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings. Molecular Oncologic Imaging. 2026;5:4–9.
MLA
Yılmaz Bildik, Bengisu, et al. “Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations With FDG PET CT Findings”. Molecular Oncologic Imaging, vol. 5, no. 3, Jan. 2026, pp. 4-9, doi:10.71286/moi.1794676.
Vancouver
1.Bengisu Yılmaz Bildik, Ediz Beyhan, Zehranur Tosunoğlu, Ahmet Ertuğrul Öztürk, Göksel Alçın, Elife Akgün, Esra Arslan. Dedifferentiated Liposarcoma: Two Case Reports of Retroperitoneal and Paratesticular Presentations with FDG PET/CT Findings. Molecular Oncologic Imaging. 2026 Jan. 1;5(3):4-9. doi:10.71286/moi.1794676